A new survey by Johnson & Johnson revealed that oncologists are overwhelmed by the rapid pace of innovation in cancer care, with many calling for better tools, education and collaboration to help integrate new treatments and technologies into everyday practice.

Here’s what you missed this week on Managed Healthcare Executive.

The research is noteworthy given a Supreme Court decision that could result in many dialysis patients switching from commercial insurance plans to Medicare.

Specialty drugs are increasingly entering general medicine. Experts at Asembia’s AXS Summit say the trend will put a premium on leveraging artificial intelligence, technology and cross-functional expertise to create more personalized, efficient patient support services.

While providers do bring up menopause with patients during visits, there are still some knowledge gaps, according to the results of a recent survey of women ages 40 to 70 and healthcare providers.

Integrated delivery networks may be crucial to meeting the challenges posed by the complexities of specialty pharmacy.

It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.

In a conversation with Managed Healthcare Executive, 10XBeta CEO Marcel Botha warned that proposed Medicaid cuts, combined with federal budget reductions under the DOGE initiative, could exacerbate the rural healthcare crisis—threatening efforts to bring mobile, community-driven innovations to underserved areas.

Kaminski and his colleagues were pioneers in applying high-throughput, genome-scale transcript profiling to advanced lung disease.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started immunotherapy. This may be one reason why these patients responded better to certain immunotherapy treatments, researchers said.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.

As ubiquitous as lab testing is in healthcare, health plans still often overlook its importance to healthcare quality and cost containment.

Capricor officials said the company was prepared for the meeting and does not expect it to delay the FDA’s decision on the therapy.

An overview of endometriosis subtypes, treatment options and costs, according to a recent research review published in JAMA.

Payers may be tempted by lower prices and no rebates, but two-thirds of the respondents said their plan has experienced an increase in the amount of rebates they have received.

A new JAMA Dermatology study found that once-daily Zoryve (roflumilast) foam, 0.3%, safely and effectively reduced scalp and body plaque psoriasis symptoms in patients 12 and older, offering a convenient, and more tolerated treatment option that may boost adherence and quality of life.

The authors provide a detailed framework for assessing the adoption of artificial intelligence.

Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.

John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a case for biomarkers in a review article published in the American Journal of Hematology.

CDC researchers report a rate of 7.1 per 100,000, an increase from 5.3 per 100,000 in a previous study. But improved diagnosis of idiopathic pulmonary fibrosis might be a factor.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

The latest report by Urban Institute warns that proposed Medicaid funding cuts could cost states like California, New York, Massachusetts and the District of Columbia hundreds of billions of dollars over the next decade.